[1] FARRELL GC, WONG VW, CHITTURI S. NAFLD in Asia-as common and important as in the West[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (5) :307-318.
|
[2] LEE SB, KIM KM, AN J, et al. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area[J]. Liver Int, 2016, 36 (9) :1351-1361.
|
[3] WONG WS, CHU CW, WONG LH, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:A population study using proton-magnetic resonance spectroscopy and transient elastography[J].Gut, 2012, 61 (3) :409-415.
|
[4] WEI JL, LEUNG JC, LOONG TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients:A population study using proton-magnetic resonance spectroscopy[J]. Am J Gastroenterol, 2015, 110 (9) :1306-1314.
|
[5] WONG LH, ESPINOSA WZ, WONG WS. Personalized management of cirrhosis by non-invasive tests of liver fibrosis[J]. Clin Mol Hepatol, 2015, 21 (3) :200-211.
|
[6] DAS K, DAS K, MUKHERJEE PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease[J]. Hepatology, 2010, 51 (5) :1593-1602.
|
[7] KARIMI-SARI H, MOUSAVI-NAEINI SM, KHONCHE A, et al. Comments on prevalence of non-alcoholic fatty liver disease and its related factors in Iran[J]. Int J Organ Transplant Med, 2017, 8 (1) :52-53.
|
[8] ZHANG H, HE SM, SUN J, et al. Prevalence and etiology of abnormal liver tests in an adult population in Jilin, China[J].Int J Med Sci, 2011, 8 (3) :254-262.
|
[9] RAGHUVANSHI T, GARG S, AGGARWAL S, et al. Prevalence of non-alcoholic fatty liver disease in non-obese non-diabetic hypothyroid North Indian population[J]. J Assoc Physicians India, 2016, 64 (1) :37.
|
[10] DING YP, LI H, ZHANG W, et al. Epidemiological characteristics and risk factors of ALT elevated nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2017, 33 (12) :2355-2360. (in Chinese) 丁玉平, 李海, 张文, 等. ALT升高的非酒精性脂肪性肝病的流行病学特征及其危险因素分析[J].临床肝胆病杂志, 2017, 33 (12) :2355-2360.
|
[11] LU ZY, SHAO Z, LI YL, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population:An 8-year follow-up study[J]. World J Gastroenterol, 2016, 22 (13) :3663-3669.
|
[12] NISHIOJI K, SUMIDA Y, KAMAGUCHI M, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012[J]. J Gastroenterol, 2015, 50 (1) :95-108.
|
[13] BRANDON OW, TAN LX, XU ZR. Nonalcoholic fatty liver disease and diabetes mellitus[J]. Clin Focus, 2017, 32 (8) :649-653. (in Chinese) BRANDON OW, 谈力欣, 许樟荣.非酒精性脂肪性肝病与糖尿病[J].临床荟萃, 2017, 32 (8) :649-653.
|
[14] DUSEJA A, SHARMA B, KUMAR A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease[J]. Hepatology, 2010, 52 (6) :2248-2249.
|
[15] CLAUS EB, CHU P, HOWE CL, et al. Pathobiologic findings in DCIS of the breast:Morphologic features, angiogenesis, HER-2/neu and hormone receptors[J]. Exp Mol Pathol, 2015, 70 (3) :303-316.
|
[16] MELLO T, MATEROZZI M, GALLI A. PPARs and mitochondrial metabolism:From NAFLD to HCC[J]. PPAR Res, 2016, 2016:7403230.
|
[17] ABE H, KAI Y, KITAHARA T, et al. Etiology of non-B nonC hepatocellular carcinoma in the eastern district of Tokyo[J]. J Gastroenterol, 2008, 43 (12) :967-974.
|
[18] SANG SL, JEONG SH, BYOUN YS, et al. Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma[J]. Bmc Cancer, 2013, 13 (1) :1-9.
|
[19] ALEXANDER J, TORBENSON M, WU TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver:A clinical and pathological study[J]. J Gastroenterol Hepatol, 2013, 28 (5) :848-854.
|
[20] TIAN JH, TANG YX. Relationship between nonalcoholic fatty liver disease and primary liver cancer[J]. Chin J New Med, 2013, 6 (8) :771-776. (in Chinese) 田景绘, 唐艳霞.非酒精性脂肪性肝病与原发性肝癌相关性探讨[J].中国临床新医学, 2013, 6 (8) :771-776.
|
[21] QIU WG. Clinicopathological features of steatohepatitic hepatocellular carcinoma and its prognosis after resection[D].Fuzhou:Fujian Medical University, 2016. (in Chinese) 邱伟刚.脂肪性肝炎肝细胞癌临床病理特点及切除术后的预后分析[D].福州:福建医科大学, 2016.
|
[22] ANGULO P. Diagnosing steatohepatitis and predicting liverrelated mortality in patients with NAFLD:Two distinct concepts[J]. Hepatology, 2011, 53 (6) :1792-1794.
|
[23] DUNN W, SANYAL AJ, BRUNT EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD) [J]. J Hepatol, 2012, 57 (2) :384-391.
|
[24] PARK SH, JEON WK, KIM SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21 (1) :138-143.
|
[25] KOZLITINA J, BOERWINKLE E, COHEN JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance[J]. Hepatology, 2011, 53 (2) :467.
|
[26] WESTON SR, LEYDEN W, MURPHY R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease[J]. Hepatology, 2015, 41:372-379.
|
[27] KO SH, BAEG MK, JUNG HS, et al. Russian Caucasians have a higher risk of erosive reflux disease compared with East Asians:A direct endoscopic comparison[J]. Neurogastroenterol Motil, 2017, 29 (5) :e13002.
|
[28] WONG VW, WONG GL, CHOI PC, et al. Disease progression of non-alcoholic fatty liver disease:A prospective study with paired liver biopsies at 3 years[J]. Gut, 2010, 59 (7) :969.
|
[29] CHITTURI S, WELTMAN M, FARRELL GC, et al. HFE mutations, hepatic iron, and fibrosis:Ethnic-specific association of NASH with C282Y but not with fibrotic severity.[J]. Hepatology, 2002, 36 (1) :142-149.
|
[30] TIAN NN, LIN XQ, QI YF, et al. Meta-analysis of genetic susceptibility of HFE gene polymorphism and nonalcoholic fatty liver disease[J]. Acad J Guangdong Pharm Coll, 2017, 33 (2) :235-240. (in Chinese) 田娜娜, 林欣琪, 祁永芬, 等. HFE基因多态性与非酒精性脂肪肝病遗传易感性的Meta分析[J].广东药学院学报, 2017, 33 (2) :235-240.
|
[31] VALENTI L, NOBILI V, AL-SERRI A, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver[J]. J Hepatol, 2011, 55 (6) :1409-1414.
|
[32] KOZLITINA J, BOERWINKLE E, COHEN JC, et al. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance[J]. Hepatology, 2011, 53 (2) :467.
|
[33] NIU TH, JIANG M, LIU HG, et al. Correlation between gene polymorphism of apolipoprotein C3 promoter region and nonalcoholic fatty liver disease[J]. Chin J Hepatol, 2014, 22 (5) :374-379. (in Chinese) 牛同红, 姜曼, 刘昊刚, 等.载脂蛋白C3启动子区基因多态性与非酒精性脂肪性肝病的相关性[J].中华肝脏病杂志, 2014, 22 (5) :374-379.
|
[34] HAO Y, TIAN XB, LIU TT, et al. MC4R expression in pedunculopontine nucleus involved in the modulation of midbrain dopamine system[J]. Int J Clin Exp Pathol, 2015, 8 (2) :2039-2043.
|
[35] CHEN KY, MUNIYAPPA R, ABEL BS, et al. RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals[J]. J Clin Endocrinol Metab, 2015, 100 (4) :1639-1645.
|
[36] CHAMBERS JC, ELLIOTT P, ZABANEH D, et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance[J]. Nat Genet, 2008, 40 (6) :716-718.
|
[37] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40 (12) :1461-1465.
|
[38] LIU JQ, ZHANG ZJ, WANG W, et al. Risk factors for nonalcoholic fatty liver disease in type 2 diabetes in adolescents[J]. World Chin J Dig, 2015, 23 (11) :1812-1817. (in Chinese) 刘建强, 张志坚, 王雯, 等.青少年非酒精性脂肪肝合并2型糖尿病的危险因素[J].世界华人消化杂志, 2015, 23 (11) :1812-1817.
|
[39] DUSEJA A, BHANSALI A, BHADADA S, et al. Nonalcoholic fatty liver disease in patients with recent onset type 2 diabetes mellitus[J]. J Gastroenterol Hepatol, 2004, 19 (Suppl) :A402.
|
[40] KALRA S, VITHALANI M, GULATI G, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT) [J]. J Assoc Physicians India, 2013, 61 (7) :448-453.
|
[41] WANG HM, LAN MJ. Ultrasound findings of liver in 172 patients with type 2 diabetes mellitus[J]. Capital Food Pharm, 2007, 14 (6) :35. (in Chinese) 王红梅, 兰明娟. 172例2型糖尿病患者肝脏的超声表现[J].首都食品与医药, 2007, 14 (6) :35.
|
[42] MOHAN V, FAROOQ S, DEEPA M, et al. Prevalence of nonalcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome[J]. Diabetes Res Clin Pract, 2009, 84 (1) :84-91.
|
[43] YOUNOSSI ZM, STEPANOVA M, RAFIQ N, et al. Pathologic criteria for nonalcoholic steatohepatitis:Interprotocol agreement and ability to predict liver-related mortality[J]. Hepatology, 2011, 53 (6) :1874-1882.
|
[44] WILLIAMSON RM, PRICE JF, GLANCY S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes:The edinburgh type 2 diabetes study[J]. Diabetes Care, 2011, 34 (5) :1139-1144.
|
[45] FAN JG, LI F, CAI XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol, 2007, 22 (7) :1086-1091.
|
[46] HASHIMOTO E, TOKUSHIGE K, FARRELL GC. Histological features of non-alcoholic fatty liver disease:What is important?[J]. J Gastroenterol Hepatol, 2012, 27 (1) :5.
|
[47] HSIEH SD, YOSHINAGA H, MUTO T, et al. Health risks among Japanese men with moderate body mass index[J]. Int J Obes Relat Metab Disord, 2000, 24 (3) :358-362.
|
[48] ARGO CK, NORTHUP PG, AL-OSAIMI AM, et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis[J]. J Hepatol, 2009, 51 (2) :371-379.
|
[49] DUSEJA A, DAS A, DHIMAN RK, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation[J]. World J Gastroenterol, 2007, 13 (4) :649.
|
[50] HUI JM, HODGE A, FARRELL GC, et al. Beyond insulin resistance in NASH:TNF-alpha or adiponectin?[J]. Hepatology, 2004, 40 (1) :46.
|
[51] PETERSEN KF, DUFOUR S, FENG J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men[J]. Proc Natl Acad Sci U S A, 2006, 103 (48) :18273-18277.
|
[52] ZHANG ZL, HUANG YS, FAN YD, et al. Effect of Xuezhikang on hepatitis and oxidative stress in rats with nonalcoholic fatty liver disease[J]. Chin J Med Offic, 2018, 46 (6) :605-609. (in Chinese) 张子龙, 黄樱硕, 范煜东, 等.血脂康对非酒精性脂肪性肝病大鼠肝炎症及氧化应激影响[J].临床军医杂志, 2018, 46 (6) :605-609.
|
[53] LIN YC, CHANG PF, YEH SJ, et al. Risk factors for liver steatosis in obese children and adolescents[J]. Pediatr Neonatol, 2010, 51 (3) :149-154.
|
[54] MARCHESINI G, FORLANI G. Diabetes and hepatocellular cancer risk:Not only a matter of hyperglycemia[J]. Hepatology, 2012, 55 (4) :1298-1300.
|
[55] HAMAGUCHI M, KOJIMA T, TAKEDA N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease[J].Ann Intern Med, 2005, 143:722-728.
|
[56] ISHIBA H, SUMIDA Y, KATAOKA S, et al. Association of coronary artery calcification with liver fibrosis in Japanese patients with NAFLD[J]. Hepatol Res, 2016, 46 (11) :1107-1117.
|
[57] CLARK JM, BRANCATI FL, DIEHL AM. The prevalence and etiology of elevated aminotransferase levels in the United States[J]. Am J Gastroenterol, 2003, 98 (5) :960-967.
|
[58] IOANNOU GN. The natural history of NAFLD:Impressively unimpressive[J]. Gastroenterology, 2005, 129 (5) :1805.
|
[59] WELLS MM, LI Z, ADDEMAN B, et al. Computed tomography measurement of hepatic steatosis:Prevalence of hepatic steatosis in a Canadian population[J]. Can J Gastroenterol Hepatol, 2016, 2016:4930987.
|
[60] BEDOGNI G, MIGLIOLI L, MASUTTI F, et al. Incidence and natural course of fatty liver in the general population:The dionysos study[J]. Hepatology, 2007, 46 (5) :1387-1391.
|
[61] CABALLERíA L, PERA G, AULADELL MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain[J]. Eur J Gastroenterol Hepatol, 2010, 22 (1) :24-32.
|